April 5, 2022 02:05 PM EDT
R&D
Pharma
Manufacturing

Boehringer In­gel­heim boosts R&D com­mit­ment, promis­es up to 15 new prod­uct launch­es by 2025

Nicole DeFeudis

Editor

Com­ing off a strong year of growth for its Eli Lil­ly-part­nered SGLT2 in­hibitor Jar­diance, Boehringer In­gel­heim is putting those gains right back in­to R&D …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

A service from the Financial Times